Covered recipient · General Payments record
KATHERINE ABELLA-RAMIREZ
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2019–2023
$1,563.97
- Reported across 85 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $302.81 | 18 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $96.73 | 6 |
| Amgen Inc. | $77.09 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $41.11 | 3 |
| PFIZER INC. | $37.80 | 2 |
| Radius Health, Inc. | $31.92 | 2 |
| GlaxoSmithKline, LLC. | $18.16 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $17.64 | 01/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996079099 | CMS |
| AbbVie Inc. | $13.55 | 01/30/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996079101 | CMS |
| AbbVie Inc. | $20.74 | 03/27/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996079103 | CMS |
| AbbVie Inc. | $13.48 | 04/24/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996079105 | CMS |
| AbbVie Inc. | $15.21 | 05/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996079107 | CMS |
| AbbVie Inc. | $16.11 | 06/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996079109 | CMS |
| Amgen Inc. | $16.31 | 03/29/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019986023 | CMS |
| Amgen Inc. | $18.02 | 07/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019986029 | CMS |
| Amgen Inc. | $20.43 | 09/13/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019986025 | CMS |
| Amgen Inc. | $22.33 | 10/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1019986027 | CMS |
| GlaxoSmithKline, LLC. | $18.16 | 04/26/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1002560331 | CMS |
| Novartis Pharmaceuticals Corporation | $13.18 | 01/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991507829 | CMS |
| Novartis Pharmaceuticals Corporation | $12.74 | 02/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991507833 | CMS |
| Novartis Pharmaceuticals Corporation | $15.19 | 05/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991507849 | CMS |
| PFIZER INC. | $16.65 | 05/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1049329681 | CMS |
| PFIZER INC. | $21.15 | 08/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1049999259 | CMS |
| Radius Health, Inc. | $15.36 | 04/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1024697839 | CMS |
| Radius Health, Inc. | $16.56 | 06/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1024697841 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2021, 2022, 2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.